News

The two-year Tsyabri (natalizumab) AFFIRM monotherapy trial achieved the two-year primary endpoint of slowing the progression of disability in patients with relapsing forms of multiple sclerosis (MS). Tsyabri

Eligard (leuprolide acetate for injectable suspension) is already approved for one-month (7.5mg), three-month (22.5mg) and four-month (30mg) formulations and Eligard 45mg was approved by the FDA on December

The investigational drug, avanafil, is a highly selective, orally administered phosphodiesterase type 5 (PDE5) inhibitor being developed by the company to treat erectile dysfunction (ED). The trial is

As part of the investment in Gamida-Cell in 2003, Teva held an option to jointly complete the development and globally commercialize StemEx. Teva will invest, under certain conditions,

The candidate is one of multiple compounds from Affinium’s Galapagos program and has been selected for its potential as an intravenous and oral antibiotic against hospital and community

ThermoDox, Celsion’s temperature-sensitive liposomal encapsulation of common cancer drug doxorubicin, allows focused, concentrated delivery of the drug to the tumor target. The phase I trial, which is being

The investigator-sponsored trial is being conducted at specialist centers in Europe and Egypt, which contains the highest prevalence of hepatitis C in the world. It will assess the

The primary objective of this study is to evaluate the safety and tolerability of single- and multiple-dose applications of Indaflex, a novel formulation of indomethacin cream. The secondary

The product, named Locteron, combines OctoPlus’ proprietary biodegradable PolyActive drug delivery technology with Biolex’ BLX-883, a recombinant alfa interferon produced in its proprietary LEX System. Locteron is designed